Scientists discover first breast cancer 'oncogene' in five years

February 18, 2011, University of Cambridge
Scientists discover first breast cancer 'oncogene' in five years

( -- Scientists have pinpointed a key cancer-causing gene that, when overactive, triggers a particularly aggressive type of breast cancer to develop.

This is the first time in over five years that scientists have discovered a new breast cancer 'oncogene' - cancer-causing genes that when overactive upset the normal checks and balances that control when and how often a cell divides.

The researchers, based at Cancer Research UK's Cambridge Research Institute at the University of Cambridge and at the British Columbia Cancer Agency in Vancouver, Canada, believe testing patients tumours to see if the gene - called 'ZNF703' - is overactive could help identify patients with more aggressive tumours, so their treatment can be tailored accordingly.

The research is published in the journal EMBO Molecular Medicine today (Friday, 18 February) alongside a study from an independent research group identifying the same gene, providing definitive evidence that ZNF703 is a genuine breast cancer .

It's thought that up to a third of more aggressive oestrogen positive breast cancers could have multiple copies of the ZNF703 gene.

If this is confirmed in larger studies it could pave the way for the development of cancer treatments specifically targeting ZNF703.

Testing for ZNF703 activity in the tumour could help reveal if patients are likely to respond to such drugs, in the same way that testing for Her2 activity is used to reveal if a patient may benefit from .

To make the discovery the researchers used 'microarray technology', which allows large numbers of tissue samples to be tested simultaneously, picking up subtle differences in gene activity between normal cells and .

Lead author Professor Carlos Caldas, from the Cancer Research UK's Cambridge Research Institute and the Department of Oncology where he is Professor of Cancer Medicine, said: "Using this state-of-the-art technology we've been able to pinpoint the precise gene behind this more aggressive type of breast cancer.

"Scientists first discovered this region of DNA may be harbouring genes linked to the development of breast cancer twenty years ago. But it's only with the technology we have today that we've been able to narrow down the search sufficiently to pinpoint the gene responsible.

"Crucially, testing whether this gene is overactive in a patient's tumour could help highlight those more likely to be resistant to standard hormone therapies, such as tamoxifen or aromatase inhibitors, helping to make sure the right drugs are matched to the right patient."

Dr Samuel Aparicio, who co-led the study and is based at the University of British Columbia and British Columbia Cancer Agency in Vancouver, Canada, said: "The discovery of ZNF703, as a new 'driver gene' in oestrogen receptor positive breast cancer, is another product of the very fruitful and long standing collaboration with our colleagues in the UK, emphasising that the fight against breast cancer takes place at the international level, with all partners bringing their unique skills and resources."

The researchers had already identified a region on human chromosome eight likely to harbour genes linked to the development of a more aggressive form of oestrogen positive breast cancer, because multiple copies of it are commonly found in tumours but not in healthy tissue.

Focusing on this region, they studied the patterns of in 1172 breast tumours, as well as breast cancer cells grown in the lab. This allowed them to eliminate one gene at a time until there was only one gene left within that region that was overactive in all the samples tested.

Crucially there were two patients in which ZNF703 was the only gene shown to be overactive, providing further evidence that it was the driving force in the development of the cancer.

Dr Lesley Walker, director of cancer information at Cancer Research UK, said: "This is the first gene of its kind to be discovered in breast cancer for five years. This is exciting because it's a prime candidate for the development of new drugs designed specifically to target tumours in which this gene is overactive. Hopefully this will lead to more effective cancer treatments in the future."

Related Stories

Recommended for you

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.